{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:44:19Z","timestamp":1790747059777,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.semarthrit.2019.09.005","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:05:24Z","timestamp":1568919924000},"page":"276-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission"],"prefix":"10.1016","volume":"50","author":[{"given":"Daniel","family":"Aletaha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Florentinus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Monastiriakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2019.09.005_bib0001","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0002","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0003","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0004","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism preliminary definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"suppl 11","key":"10.1016\/j.semarthrit.2019.09.005_bib0005","first-page":"S14","volume":"63","author":"Anderson","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0006","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0007","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/art.23945","article-title":"An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis","volume":"58","author":"Brown","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0008","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.22190","article-title":"Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression","volume":"54","author":"Brown","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0009","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0010","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ard.2005.037333","article-title":"Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?","volume":"64","author":"Makinen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0011","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/art.30634","article-title":"Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints","volume":"63","author":"Aletaha","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0012","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","article-title":"Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition","volume":"19","author":"Schoels","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.39945","article-title":"Comparative assessment of the different American College of Rheumatology\/European League Against Rheumatism remission definitions for rheumatoid arthritis for their use as clinical trial end points","volume":"69","author":"Mack","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0014","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/annrheumdis-2012-201519","article-title":"Near misses of ACR\/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions","volume":"71","author":"Studenic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0015","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/art.34540","article-title":"Patient's global assessment of disease activity: what are we measuring?","volume":"64","author":"van Tuyl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0016","first-page":"S45","article-title":"Remission of rheumatoid arthritis: should we care about definitions?","volume":"24","author":"Aletaha","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0018","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0019","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0021","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0022","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","article-title":"How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?","volume":"74","author":"Fleischmann","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0023","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000578","article-title":"Physician global assessments for disease activity in rheumatoid arthritis are all over the map!","volume":"4","author":"Turk","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activitymeasures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0026","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/art.34543","article-title":"Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity","volume":"64","author":"Studenic","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0027","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/acr.22902","article-title":"Patient\u2013physician discordance in global assessment in rheumatoid arthritis: a systematic literature review with meta-analysis","volume":"68","author":"Desthieux","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0028","doi-asserted-by":"crossref","first-page":"R221","DOI":"10.1186\/ar4421","article-title":"Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder","volume":"15","author":"Balogh","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0029","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.20132","article-title":"Patient\u2013physician discordance in assessments of global disease severity in rheumatoid arthritis","volume":"62","author":"Barton","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0030","first-page":"425","article-title":"Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants","volume":"21","author":"van Leeuwen","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0031","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/annrheumdis-2016-209463","article-title":"Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis","volume":"76","author":"Baker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0032","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/ard.2010.149260","article-title":"Association with joint damage and physical functioning of nine composite indices and the 2011 ACR\/EULAR remission criteria in rheumatoid arthritis","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0033","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.39996","article-title":"Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria","volume":"69","author":"Smolen","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0034","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","article-title":"Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0036","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/annrheumdis-2012-201821","article-title":"Performance of the 2011 ACR\/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis","volume":"72","author":"Thiele","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0037","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: 2-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.09.005_bib0038","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219302860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219302860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:02:23Z","timestamp":1758733343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017219302860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0049017219302860"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}